Regeneron Pharmaceuticals (REGN) Long-Term Deferred Tax (2011 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Long-Term Deferred Tax of $4.4 billion for Q2 2026, up 22.65% year-over-year from $3.6 billion in Q2 2025, and up 4.55% quarter-over-quarter from $4.2 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Long-Term Deferred Tax (2011 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Long-Term Deferred Tax history runs 16 years deep, the most recent figure standing at $4.4 billion for Q2 2026.
- In Q2 2026, Long-Term Deferred Tax rose 22.65% year-over-year to $4.4 billion; the TTM figure through Jun 2026 stood at $4.4 billion (up 22.65% YoY), while the FY2025 annual figure was $4.1 billion, up 23.03% from the prior year.
- Long-Term Deferred Tax for Q2 2026 stood at $4.4 billion, up from $4.2 billion in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $4.4 billion in Q2 2026, with the low at $1.1 billion in Q1 2022.
- The 5-year median for Long-Term Deferred Tax is $2.8 billion (2024), against an average of $2.8 billion.
- The sharpest annual moves came in 2022 and 2026: Long-Term Deferred Tax soared 100.79% in 2022, then gained 21.73% in 2026.
- Regeneron Pharmaceuticals' Long-Term Deferred Tax stood at $1.7 billion in 2022, then jumped by 49.41% to $2.6 billion in 2023, then rose by 28.68% to $3.3 billion in 2024, then increased by 23.03% to $4.1 billion in 2025, then increased by 7.46% to $4.4 billion in 2026.
- Business Quant data shows REGN's Long-Term Deferred Tax at $4.4 billion in Q2 2026, $4.2 billion in Q1 2026, and $4.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.38 Bn |
| Mar 31, 2026 | 4.19 Bn |
| Dec 31, 2025 | 4.08 Bn |
| Sep 30, 2025 | 3.85 Bn |
| Jun 30, 2025 | 3.57 Bn |
| Mar 31, 2025 | 3.44 Bn |
| Dec 31, 2024 | 3.31 Bn |
| Sep 30, 2024 | 3.02 Bn |
| Jun 30, 2024 | 2.88 Bn |
| Mar 31, 2024 | 2.76 Bn |
| Dec 31, 2023 | 2.58 Bn |
| Sep 30, 2023 | 2.32 Bn |
| Jun 30, 2023 | 2.14 Bn |
| Mar 31, 2023 | 1.92 Bn |
| Dec 31, 2022 | 1.72 Bn |
| Sep 30, 2022 | 1.45 Bn |
| Jun 30, 2022 | 1.35 Bn |
| Mar 31, 2022 | 1.14 Bn |
| Dec 31, 2021 | 876.90 Mn |
| Sep 30, 2021 | 723.20 Mn |